Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $585.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -100.32%
• EPS Growth: -197.69%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 89,141,090
• 10 Day Avg. Volume: 2,850,394
• 30 Day Avg. Volume: 1,505,690
• PEG Ratio: -0.13
• Price to Book (P/B): 7.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.47
• Enterprise Value/Market Cap: 4.10
• Enterprise Value/Revenue: 4.13
• Enterprise Value/Gross Profit: -243.37
• Enterprise Value/Ebitda: -3.04
• 1Y Price Target: $12.17
• Price Target Upside: 93.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 58 Neutral
• Price Target: $6.50 ▲(3.17%Upside)

Amylyx Pharmaceuticals' stock score is primarily impacted by its financial performance, which reveals significant challenges, including declining revenues and cash flow issues. However, strong technical indicators and positive developments from the earnings call provide some balance, indicating potential for future growth amid current operational struggles.

Positive Factors

Clinical Trial Success

The 24-week data from the HELIOS trial demonstrated consistent improvements in C-peptide levels, indicating a slowing of disease progression in Wolfram syndrome patients.

Market Opportunity

Avexitide is expected to derive real value to the name and is the reason for the recent upgrade of the stock.

Stock Upgrade

Analyst's recommendation upgrades the stock rating to Outperform with a price target increase from $4.00 to $10.00.

Negative Factors

Competition

Avexitide is expected to be the first drug approved for post-bariatric hypoglycemia, a chronic condition with no current treatment.

Regulatory Challenges

The company is currently engaging with the FDA and believes that the current data will inform the design of the Phase 3 trial.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Amylyx Pharmaceuticals Inc generates revenue primarily through the commercialization of its therapeutic products. The company's revenue model is centered around the sale of AMX0035, which has been developed for the treatment of neurodegenerative diseases like ALS. Revenue streams include product sales in approved markets and potential partnerships or collaborations with other pharmaceutical companies for distribution and further development. Regulatory approvals and successful market penetration are significant factors contributing to its earnings. However, as a company in the biotechnology industry, research and development activities also play a crucial role in advancing its pipeline and supporting future revenue growth.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Amylyx Pharmaceuticals is experiencing significant financial challenges with declining revenues and substantial operational losses. Despite a low debt-to-equity ratio and a strong equity ratio, the company has faced historical negative equity. Cash flow issues are evident with a significant decline in free cash flow, indicating ongoing cash generation challenges.

Income Statement

The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.

Balance Sheet

Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.

Cash Flow

The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-1.27M	87.37M	380.79M	22.23M	285.00K	650.00K
Gross Profit	-9.87M	-37.26M	355.35M	19.24M	233.00K	-23.94M
EBITDA	-170.60M	-301.23M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-218.86M	-301.74M	49.27M	-198.38M	-87.88M	-44.84M
Balance Sheet
Total Assets	219.68M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	204.07M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	1.38M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	18.26M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	201.42M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-207.08M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-206.98M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	31.18M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	65.88M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 6.3 is above the 20-day moving average (MA) of 5.76, above the 50-day MA of 5.29, and above the 200-day MA of 4.34, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 61.36 is Neutral, neither overbought nor oversold. The STOCH value of 81.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%
AMLX	58 Neutral	$585.66M	―	-83.24%	―	-100.32%	-197.69%
ETON	58 Neutral	$387.51M	―	-22.95%	―	40.88%	-579.73%
CKPT	45 Neutral	$370.71M	―	-1869.55%	―	-60.19%	56.60%
ALLO	43 Neutral	$262.48M	―	-59.60%	―	-100.00%	31.43%
ZBIO	42 Neutral	$427.55M	―	-115.47%	―	―	―
BNTC	42 Neutral	$334.43M	―	-48.57%	―	-100.00%	83.98%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting

On June 5, 2025, Amylyx Pharmaceuticals Inc. held its Annual Meeting of Stockholders where three key proposals were voted on. The stockholders elected Karen Firestone, Justin Klee, and Bernhardt Zeiher, M.D. as Class I directors for a three-year term. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on an advisory basis, the compensation of the Company’s named executive officers.

The most recent analyst rating on (AMLX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.